BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37898239)

  • 1. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
    Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
    Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
    J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma.
    Liang JH; Zhang YP; Xia J; Ding CY; Wu W; Wang L; Cao L; Zhu HY; Fan L; Li TN; Li JY; Xu W
    Cancer Res Treat; 2019 Oct; 51(4):1479-1487. PubMed ID: 30913868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden.
    Leccisotti L; Maccora D; Malafronte R; D'Alò F; Maiolo E; Annunziata S; Rufini V; Giordano A; Hohaus S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2783-2791. PubMed ID: 35779106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
    Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of interim
    Sun N; Qiao W; Xing Y; Wang T; Zhao J
    Ann Hematol; 2023 Apr; 102(4):795-800. PubMed ID: 36806973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
    Vercellino L; Cottereau AS; Casasnovas O; Tilly H; Feugier P; Chartier L; Fruchart C; Roulin L; Oberic L; Pica GM; Ribrag V; Abraham J; Simon M; Gonzalez H; Bouabdallah R; Fitoussi O; Sebban C; López-Guillermo A; Sanhes L; Morschhauser F; Trotman J; Corront B; Choufi B; Snauwaert S; Godmer P; Briere J; Salles G; Gaulard P; Meignan M; Thieblemont C
    Blood; 2020 Apr; 135(16):1396-1405. PubMed ID: 31978225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
    Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
    Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
    Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
    J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
    Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
    Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma.
    Draye-Carbonnier S; Camus V; Becker S; Tonnelet D; Lévêque E; Zduniak A; Jardin F; Tilly H; Vera P; Decazes P
    Sci Rep; 2024 Apr; 14(1):8033. PubMed ID: 38580734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline [
    Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma.
    So H; Lee H; Hyun SH; Cho YS; Moon SH; Choi JY; Lee KH
    Front Oncol; 2023; 13():1283582. PubMed ID: 38023238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Extensive Analysis of
    Louarn N; Galicier L; Bertinchamp R; Lussato D; Montravers F; Oksenhendler É; Merlet P; Gérard L; Vercellino L
    J Clin Oncol; 2022 Apr; 40(12):1346-1355. PubMed ID: 35073166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
    Jin P; Bai M; Liu J; Yu J; Meng X
    Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma.
    Major A; Hammes A; Schmidt MQ; Morgan R; Abbott D; Kamdar M
    Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):39-46. PubMed ID: 31761712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.